CL2021001882A1 - Composición líquida de clotrimazol envasada de dosis única. - Google Patents

Composición líquida de clotrimazol envasada de dosis única.

Info

Publication number
CL2021001882A1
CL2021001882A1 CL2021001882A CL2021001882A CL2021001882A1 CL 2021001882 A1 CL2021001882 A1 CL 2021001882A1 CL 2021001882 A CL2021001882 A CL 2021001882A CL 2021001882 A CL2021001882 A CL 2021001882A CL 2021001882 A1 CL2021001882 A1 CL 2021001882A1
Authority
CL
Chile
Prior art keywords
single dose
composition
liquid composition
clotrimazole
pharmaceutically
Prior art date
Application number
CL2021001882A
Other languages
English (en)
Inventor
Mendoza Maria Mar Terraz
Aquilué Javier Sanagustín
Molina Adolfo Téllez
Gañán María Isabel Delgado
Original Assignee
Salvat Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salvat Lab Sa filed Critical Salvat Lab Sa
Publication of CL2021001882A1 publication Critical patent/CL2021001882A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a una unidad de envasado de dosis única que es un envase de soplado, llenado y sellado (blow-fill-seal, BFS) que comprende una composición líquida estéril farmacéutica o veterinaria que es una solución, donde a) la composición comprende una cantidad terapéuticamente efectiva de clotrimazol o una sal farmacéutica o veterinariamente aceptable del mismo, junto con uno o más excipientes o vehículos farmacéutica o veterinariamente aceptables, y b) el envase tiene un volumen desde 0,05 hasta 8 mL, con la condición de que el contenido de agua de la composición es igual o inferior al 4% en peso con respecto al peso total de la composición. También se refiere a un envase secundario que comprende una o más unidades de envasado de dosis única.
CL2021001882A 2019-02-19 2021-07-15 Composición líquida de clotrimazol envasada de dosis única. CL2021001882A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19382120 2019-02-19

Publications (1)

Publication Number Publication Date
CL2021001882A1 true CL2021001882A1 (es) 2022-02-11

Family

ID=65766941

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001882A CL2021001882A1 (es) 2019-02-19 2021-07-15 Composición líquida de clotrimazol envasada de dosis única.

Country Status (28)

Country Link
US (1) US12246006B2 (es)
EP (1) EP3927310B1 (es)
JP (1) JP7514844B2 (es)
KR (1) KR102940238B1 (es)
CN (1) CN113423382B (es)
AU (1) AU2020225663B2 (es)
CA (1) CA3127151A1 (es)
CL (1) CL2021001882A1 (es)
CO (1) CO2021010326A2 (es)
CR (1) CR20210473A (es)
DO (1) DOP2021000169A (es)
ES (1) ES2980452T3 (es)
HR (1) HRP20240866T1 (es)
HU (1) HUE067872T2 (es)
IL (1) IL284858B2 (es)
MA (1) MA55007B1 (es)
MD (1) MD3927310T2 (es)
MX (1) MX2021008803A (es)
PE (1) PE20211892A1 (es)
PH (1) PH12021551694A1 (es)
PL (1) PL3927310T3 (es)
RS (1) RS65657B1 (es)
SA (1) SA521422538B1 (es)
SG (1) SG11202107773RA (es)
SM (1) SMT202400262T1 (es)
TW (1) TWI834808B (es)
WO (1) WO2020169611A1 (es)
ZA (1) ZA202105236B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017187262A1 (en) 2016-04-25 2017-11-02 Marc Andrew Koska Medical delivery system
EP3710086A4 (en) 2017-11-17 2021-11-17 Koska Family Limited SYSTEMS AND PROCEDURES FOR LIQUID DISPENSER
US12544511B2 (en) 2018-06-20 2026-02-10 Koska Family Limited Systems and methods for pre-filled dual-chamber medical agent delivery
WO2021207282A2 (en) 2020-04-07 2021-10-14 Combangio, Inc. Lyophilized mesenchymal stem cell derived secretome and uses thereof
USD1052082S1 (en) 2020-06-01 2024-11-19 Koska Family Limited Sealed fluid container
JP2025530090A (ja) * 2022-09-07 2025-09-11 コンバンジョ・インコーポレイテッド 間葉系幹細胞由来セクレトームの調製及び精製方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5598112A (en) 1979-01-17 1980-07-25 Sumitomo Chem Co Ltd Liquid medicine for external use
JP2555555B2 (ja) * 1991-07-03 1996-11-20 武田薬品工業株式会社 抗真菌性外用製剤
CA2563365A1 (en) 2004-04-23 2005-11-03 Mystic Pharmaceuticals, Inc. Multiple unit dose drug delivery system
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
EP1712220A1 (en) * 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
KR20090100358A (ko) 2006-11-16 2009-09-23 이-테라퓨틱스 리미티드 스타필로로커스 감염의 치료를 위한 클로트리마졸
GB0700380D0 (en) 2007-01-09 2007-02-14 Breath Ltd Storage Of Ampoules
DE102007056462B4 (de) * 2007-11-23 2011-10-27 Pari Pharma Gmbh Einwegampulle für eine Vorrichtung zur Erzeugung von Aerosolen
WO2011121604A2 (en) * 2010-03-29 2011-10-06 Lincoln Pharmaceuticals Limited A liquid vaginal spray formulation for treatment of vaginal fungal infection
ES2565353T3 (es) * 2010-12-16 2016-04-04 Borje S. Andersson Formulaciones farmacéuticas de azol para administración parenteral y métodos para la preparación y el uso de las mismas como tratamiento de enfermedades sensibles a los compuestos de azol
US8933112B2 (en) 2012-06-15 2015-01-13 Memphaceuticals, LLC Topical liquid to ameliorate pain and promote healing of burn-injured skin
US9849126B2 (en) 2013-01-03 2017-12-26 Entrx LLC Sterile otic formulations

Also Published As

Publication number Publication date
IL284858B1 (en) 2025-06-01
EP3927310B1 (en) 2024-04-10
CN113423382A (zh) 2021-09-21
EP3927310A1 (en) 2021-12-29
JP2022520714A (ja) 2022-04-01
KR102940238B1 (ko) 2026-03-16
US12246006B2 (en) 2025-03-11
RS65657B1 (sr) 2024-07-31
DOP2021000169A (es) 2021-09-30
CR20210473A (es) 2021-10-08
AU2020225663A1 (en) 2021-08-12
ES2980452T3 (es) 2024-10-01
CN113423382B (zh) 2024-10-29
MX2021008803A (es) 2021-11-12
TWI834808B (zh) 2024-03-11
PL3927310T3 (pl) 2024-08-05
SG11202107773RA (en) 2021-08-30
MA55007A (fr) 2021-12-29
MD3927310T2 (ro) 2024-08-31
EP3927310C0 (en) 2024-04-10
CA3127151A1 (en) 2020-08-27
KR20210131313A (ko) 2021-11-02
WO2020169611A1 (en) 2020-08-27
SMT202400262T1 (it) 2024-07-09
PH12021551694A1 (en) 2022-05-11
IL284858A (en) 2021-08-31
MA55007B1 (fr) 2024-06-28
HRP20240866T1 (hr) 2024-10-11
PE20211892A1 (es) 2021-09-22
IL284858B2 (en) 2025-10-01
JP7514844B2 (ja) 2024-07-11
CO2021010326A2 (es) 2021-08-19
ZA202105236B (en) 2023-10-25
AU2020225663B2 (en) 2024-03-14
SA521422538B1 (ar) 2024-03-28
TW202045161A (zh) 2020-12-16
US20220133695A1 (en) 2022-05-05
HUE067872T2 (hu) 2024-11-28

Similar Documents

Publication Publication Date Title
CL2021001882A1 (es) Composición líquida de clotrimazol envasada de dosis única.
BR112014008551A2 (pt) conjunto de válvulas para uso com recipiente de líquido e frasco de medicamento
AR130238A2 (es) Método para reducir la cantidad del producto de degradación dp3 durante la vida de estante de una composición farmacéutica en solución para aerosol y uso de un envase de aerosol asociado
PE20160681A1 (es) Formulacion de premezcla de dexmedetomidina
CL2021000290A1 (es) Un método de obtención de la forma de dosis líquida del medicamento edaravone, que es estable durante el almacenamiento, transporte y de uso conveniente
AR038313A1 (es) Cartucho de polvo medicamentoso e inhalador provisto de ese cartucho
UY32760A (es) Composición farmacéutica para un inhibidor de proteasa del virus de la hepatitis c
JP2022062078A5 (es)
EP1981760A4 (en) ROBOT DRIVE MACHINE FOR THE AUTOMATED PACKAGING OF PHARMACEUTICAL SOLID PRODUCTS
SV2017005596A (es) Unidad de dosificacion orodispersable que contiene un componente estetrol
GB2484220A (en) Dispensing system for medicament regime
EP4368175A3 (en) Perfusion dosage form
MX2021002054A (es) Productos que contienen cannabinoides, contenedores, sistemas y métodos.
CO2019009613A2 (es) Procedimiento para el llenado gravimétrico en condiciones estériles de sólidos en un contenedor farmacéutico
EA202090697A1 (ru) Устройство для упаковывания дозированных количеств твердых лекарственных средств
MX2024010767A (es) Kit, formulacion y metodos de gliburida de baja sorcion.
UY38165A (es) Envase estéril flexible con compensador de presión para la reconstitución dosificada de sustancias medicinales o nutricionales fluidas para su administración a los pacientes mediante perfusión o inyección
MX2017016862A (es) Composicion farmaceutica estable para administracion oral.
UY39658A (es) Formulación y métodos de gliburida de baja absorción
AR112265A1 (es) Antagonista del receptor de angiotensina ii para la prevención o tratamiento de enfermedades sistémicas en gatos
CL2023003478A1 (es) Recipiente para medicamentos, comprende composición farmacéutica líquida 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina
JP2006025953A (ja) ホリナート類水溶液充填プレフィルドシリンジ包装体
ECSDI23001190S (es) Envase de embalaje para medicamento
ECSDI23001193S (es) Envase de embalaje para medicamento
AR089710A1 (es) Composiciones farmaceuticas estabilizadas de un inhibidor del virus de hepatitis c